Literature DB >> 16702794

Prevalence of active hepatitis C virus infection in patients with systemic lupus erythematosus.

M Mubashir Ahmed1, Seth Mark Berney, Robert E Wolf, Michelene Hearth-Holmes, Samina Hayat, Eisha Mubashir, Henri Vanderheyde, Wun-Ling Chang, John W King.   

Abstract

OBJECTIVE: Hepatitis C virus (HCV) infection is associated with various autoimmune disorders and can mimic systemic lupus erythematosus (SLE) clinically and serologically. There are few reports of prevalence of HCV infection in patients with SLE. The aim of this study was to determine the prevalence of HCV viremia by polymerase chain reaction (PCR) in patients with SLE.
METHODS: We tested sera from 40 consecutive patients with SLE collected from 1993 to 2000. All of the patients had HCV viral load measured by PCR. The results were compared with the prevalence of HCV viremia in a control group of blood donors in our geographic area as well as in United States general population.
RESULTS: HCV was detected in 4 of 40 patients (10%). The prevalence of HCV in our area blood donors is 130 cases per 100,000 persons (0.13%; P<0.0001). The prevalence of HCV infection in the United States general population, screened by PCR, is 1330 cases per 100,000 people (1.33%; P=0.002). The prevalence of HCV infection was significantly higher in our SLE patients than in our area blood donors. The frequency of HCV infection was also higher than that of the United States general population.
CONCLUSION: Our observations support those of other investigators who have reported an increased prevalence of HCV infection in SLE patients. Further detailed investigation of this association may help in understanding the pathogenesis of SLE. HCV infection should be tested when the diagnosis of SLE is considered.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16702794     DOI: 10.1097/00000441-200605000-00003

Source DB:  PubMed          Journal:  Am J Med Sci        ISSN: 0002-9629            Impact factor:   2.378


  10 in total

1.  Hepatitis C virus infection and its rheumatologic implications.

Authors:  Zeynel A Sayiner; Uzma Haque; Mohammad U Malik; Ahmet Gurakar
Journal:  Gastroenterol Hepatol (N Y)       Date:  2014-05

Review 2.  Challenge of liver disease in systemic lupus erythematosus: Clues for diagnosis and hints for pathogenesis.

Authors:  Fernando Bessone; Natalia Poles; Marcelo G Roma
Journal:  World J Hepatol       Date:  2014-06-27

Review 3.  Malignancies in systemic lupus erythematosus: a 2015 update.

Authors:  Gillian C Goobie; Sasha Bernatsky; Rosalind Ramsey-Goldman; Ann E Clarke
Journal:  Curr Opin Rheumatol       Date:  2015-09       Impact factor: 5.006

4.  Cancer risk in a cohort of patients with systemic lupus erythematosus (SLE) in California.

Authors:  Arti Parikh-Patel; Richard H White; Mark Allen; Rosemary Cress
Journal:  Cancer Causes Control       Date:  2008-04-02       Impact factor: 2.506

5.  Anti-glutamic Acid decarboxylase antibody-associated ataxia as an extrahepatic autoimmune manifestation of hepatitis C infection: a case report.

Authors:  Amer Awad; Olaf Stüve; Marlyn Mayo; Rafeed Alkawadri; Bachir Estephan
Journal:  Case Rep Neurol Med       Date:  2011-07-10

6.  Liver perivascular epithelioid cell tumor in a patient with systemic lupus erythematosus.

Authors:  Paraskevi V Voulgari; Vissaria Tatsi; Haralampos J Milionis; Anna Goussia; Vasileios Xydis; George K Glantzounis
Journal:  Int J Surg Case Rep       Date:  2018-11-01

Review 7.  Extrahepatic manifestations associated with Chronic Hepatitis C Virus Infection.

Authors:  A Flores-Chávez; J A Carrion; X Forns; M Ramos-Casals
Journal:  Rev Esp Sanid Penit       Date:  2017-12

8.  Development and management of systemic lupus erythematosus in an HIV-infected man with hepatitis C and B co-infection following interferon therapy: a case report.

Authors:  Iain J Abbott; Christina C Chang; Matthew J Skinner; Alison Street; Greg Perry; Catriona McLean; Edwina J Wright; Paul U Cameron
Journal:  J Med Case Rep       Date:  2009-06-10

9.  The HLA Region and Autoimmune Disease: Associations and Mechanisms of Action.

Authors:  S C L Gough; M J Simmonds
Journal:  Curr Genomics       Date:  2007-11       Impact factor: 2.236

10.  Sustained virological response to hepatitis C therapy does not decrease the incidence of systemic lupus erythematosus or rheumatoid arthritis.

Authors:  Wei-Fan Hsu; Chi-Yi Chen; Kuo-Chih Tseng; Hsueh-Chou Lai; Hsing-Tao Kuo; Chao-Hung Hung; Shui-Yi Tung; Jing-Houng Wang; Jyh-Jou Chen; Pei-Lun Lee; Rong-Nan Chien; Chun-Yen Lin; Chi-Chieh Yang; Gin-Ho Lo; Chi-Ming Tai; Chih-Wen Lin; Jia-Horng Kao; Chun-Jen Liu; Chen-Hua Liu; Sheng-Lei Yan; Ming-Jong Bair; Wei-Wen Su; Cheng-Hsin Chu; Chih-Jen Chen; Ching-Chu Lo; Pin-Nan Cheng; Yen-Cheng Chiu; Chia-Chi Wang; Jin-Shiung Cheng; Wei-Lun Tsai; Han-Chieh Lin; Yi-Hsiang Huang; Pei-Chien Tsai; Jee-Fu Huang; Chia-Yen Dai; Wan-Long Chuang; Ming-Lung Yu; Cheng-Yuan Peng
Journal:  Sci Rep       Date:  2020-03-25       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.